Richard A. Frank, MD, PhD, FFPM (RCP)
Vice president, Global Medical Affairs and Clinical Strategy,
GE Healthcare
In the pharmaceutical industry Dr Frank conducted more than 100 clinical trials across all therapeutic areas and has gained regulatory approval for 4 drugs in the US and EU in addition to clinical pharmacology labeling for a wide range of drugs. He built one of the first Translational Medicine Departments in the pharmaceutical industry, including clinicians, statisticians and technologists in disciplines ranging from gene banking and in vitro diagnostics to radiology and nuclear medicine.
In GE Healthcare, Richard built the clinical trials program and gained approval for a number of novel devices in the US and EU including mammography and colonography products. He is active in collaborations with the NIH, FDA, and pharmaceutical industry.
Richard is a past president of the Society of Non-invasive Imaging in Drug Development [a council of the Academy of Molecular Imaging] and now chairs the FDG-PETCT workgroup of RSNA’s Quantitative Imaging Biomarkers Alliance as well as AMI’s Institute of Molecular Technology (cf Annual Report).
Richard is licensed to practice medicine in the State of New York and serves on various Institute of Medicine working groups, medical advisory boards, and editorial boards including Molecular Imaging and Biology. He is a member of SNM’s Molecular Imaging Center of Excellence, AdvaMed’s Clinical and Regulatory Affairs Committee, and a Fellow of the Faculty of Pharmaceutical Medicine, Royal College of Physicians. |
